Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Clear all
Active, not recruiting Phase 3 Interventional

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
sunvozertinib, Pemetrexed+carboplatin
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Glendale, California • Vallejo, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Recruiting Not applicable Interventional

A Study of Time-Restricted Eating in Childhood Cancer Survivors

NCT07009288
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Children's Oncology Group Heart Health Link, Monthly weights, Fasting, Calls, Participant Questionnaires, Dried blood spot
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Active, not recruiting Not applicable Interventional

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

NCT04888988
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
93
States / cities
Fresno, California • Martinez, California • Roseville, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT00058461
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma
Interventions
ifosfamide, etoposide, rituximab, carboplatin, filgrastim, methotrexate, cytarabine, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

NCT00640861
View directory record Official record
Conditions
Breast Cancer
Interventions
CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

NCT06555783
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View directory record Official record
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 25, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional

Proton Beam Therapy to Treat Esophageal Cancer

NCT02023541
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, Adenocarcinoma Of Esophagus
Interventions
Proton beam therapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jun 25, 2026, 4:31 PM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation

NCT00214266
View directory record Official record
Conditions
Renal Transplantation
Interventions
Campath 1H®, Rituximab, mycophenolate mofetil
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

NCT00002556
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
vincristine sulfate, carmustine, melphalan, cyclophosphamide, prednisone, recombinant interferon alfa-2b, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

NCT01195922
View directory record Official record
Conditions
Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01246622
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions
cytarabine, lenalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 3 Interventional

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
16
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00439231
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Georg Aue, M.D.
NIH
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Impact of a Psychological Biofeedback-Relaxation Intervention on Clinical, Physical and Psychological Outcomes in Patients With Heart Failure

NCT00255931
View directory record Official record
Conditions
Heart Failure
Interventions
Cognitive Behavioral Therapy, Attention Placebo
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
21 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Azixa
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Jun 25, 2026, 4:31 PM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Not applicable Interventional

Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis

NCT03805737
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Amulez and sunlight, Amulez and red light treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jun 25, 2026, 4:31 PM EDT
Terminated Not applicable Interventional Results available

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

NCT00631137
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Interventions
testosterone gel applied to skin, whey powder protein
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bone Response to Soy Isoflavones in Women

NCT00043745
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Soy isoflavones, Extract tablets
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Davis, California • Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jun 25, 2026, 4:31 PM EDT
Completed Phase 3 Interventional

Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

NCT05660772
View directory record Official record
Conditions
Knee Osteoarthritis, Osteo Arthritis Knee
Interventions
Microfragmented Adipose Tissue, Corticosteroid
Device · Drug
Lead sponsor
Lipogems International spa
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Gulf Breeze, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jun 25, 2026, 4:31 PM EDT
Recruiting Phase 2 Interventional

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Duarte, California • Atlanta, Georgia • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 25, 2026, 4:31 PM EDT
Recruiting Phase 1 Interventional

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

NCT05003895
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma
Interventions
Cyclophosphamide, CAR-T cell, Fludarabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 25, 2026, 4:31 PM EDT